Biomedical group Inferity specialises in advanced data management in health care, in diagnosis and in Artificial Intelligence. The chief mission and goal is a decentralised and democratised healthcare system which massively employes the latest technology. This will enable enable access to a highly individualised approach not only for patients but also to healthy individuals. 

Inferity was created in 2021 from a merger between Natland's Anygence Company and a startup company Aiolite. Among other activities, Anygence runs Covid-19 testing centres in Prague, Brno and Ostrava, the three largest cities in the Czech Republic.

Investment year: 2021 Stake: Minority
Segment: B2C Market: Czechia